Methods for treating amyotrophic lateral sclerosis (ALS). The methods include administering to a subject in need thereof a therapeutically effective amount of at least one small conductance calcium-activated potassium (SK) channel activator or a pharmaceutically acceptable salt or solvate thereof. Pharmaceutical compositions for the treatment of ALS, including a therapeutically effective amount of at least one SK channel activator, or a pharmaceutically acceptable salt or solvate thereof, and at least one excipient, adjuvant, or pharmaceutically acceptable carrier.